Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Contributed by: GlobeNewswire

Tags

cancer

More Like This

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024